-
Yemen's Houthis seize key city on Red Sea: military source
-
Russian skater Valieva loses neutral status
-
Oil prices extend gains as markets await ECB rate outlook
-
Will Israel's right exploit sanctions in run-up to vote?
-
Wars pose a test as India hosts BRICS summit with China, Russia, Iran leaders
-
'Metal Gear' creator moves to Xbox after Playstation cancellation
-
Messi to buy second Spanish lower league club
-
Indonesia rescues six orangutans from fires in a week
-
Pochettino calls for Chelsea to lose 2016-17 Premier League title
-
Macron urges Europe to develop 'crewed spaceflight' programme
-
North Korea leader's daughter believed to have younger sibling: Seoul
-
Deals worth billions to be signed as UAE leader visits Germany
-
Wars pose a test as India hosts BRICS summit with Russia, Iran leaders
-
Zamanat Targets GCC’s $250 Billion SME Financing Gap With Up to $100 Million Tokenized Private Credit Fund
-
Alessio Vinassa Unveils an Emerging Technology Investment Approach Shaped by Financial Challenges
-
Sri Lanka court revokes monk's pardon, orders return to prison
-
Stocks drop as oil spike fans inflation and interest rate fears
-
'Hopeless, stuck, afraid': US deportees in limbo in Cameroon
-
Portugal harvests grapes at night to beat the heat
-
Mount Fuji ends hiking season with landslide, two rescues
-
Philippine ferry fire kills 5, dozens missing
-
Seahawks beat Patriots again in NFL opener
-
Oil prices flare as Iran tightens grip on Hormuz
-
Asian Games begin with Qatar basketball win, nine days before opening ceremony
-
Japan gymnasts under injury cloud for home Asian Games
-
Stocks sink as oil rally fans inflation and rate hike fears
-
India trailblazer won't 'let go' of chance for Asian weightlifting glory
-
Argentine industry reels from Milei's free-market revolution
-
Zverev cruises past van de Zandschulp into US Open semis
-
Women quit South Korea's grind for diving tradition
-
Myanmar tin mega-mine restarts operations: think tank
-
Bayeux Tapestry 'mania' sweeps UK as sold-out exhibition opens
-
Online and undercover: saving trafficked wildlife in Thailand
-
August hottest month ever recorded globally: EU monitor
-
Antonelli faces new challenge after stirring triumph in Monza
-
Duplantis leads creme de la creme at 'game-changing' Ultimate Championship
-
Korda leads US bid to win first away Solheim Cup since 2015
-
Sjobo, cradle of Sweden's now-mainstream anti-migrant sentiment
-
Eurozone rate-setters to hike borrowing costs as energy prices jump
-
Israeli-made film about Gaza civilian deaths to debut in Venice
-
As oceans warm, Florida scientists hunt for heat-resistant coral
-
Stars ready for busy Toronto International Film Festival
-
Trump takes center stage as Republicans fight midterm tide
-
Rubio defends anti-drug boat strikes, warns of cartel 'cancer'
-
Gauff takes inspiration from Tiafoe in US Open fightback win
-
Rybakina books US Open semi against Gauff, secures No.1 ranking
-
Ralph Lauren opens fur-free New York Fashion Week
-
Pegula aiming to thwart Sabalenka three-peat in US Open semis
-
Arteta lauds in-form Odegaard as 'remarkable' Arsenal edge Napoli
-
'Not normal' US Open scheduling under-fire after late-night finishes
US court restricts access to abortion pill, ruling on hold
A US federal appeals court on Wednesday imposed restrictions on a widely used abortion pill, but the ruling will remain on hold as the Supreme Court decides whether to hear the case.
The ruling by a three-judge panel of the New Orleans-based 5th Circuit Court of Appeals would limit use of mifepristone to the first seven weeks of pregnancy, instead of 10, and block it from being distributed by mail.
It would also require the abortion pill, which accounts for more than half of the abortions in the United States, to be prescribed by a doctor.
Despite the ruling by the panel of conservative judges, two of whom were appointed by former president Donald Trump and one by former president George W. Bush, the drug will remain on the market for the time being.
Anti-abortion groups are seeking to have mifepristone banned, claiming despite its long track record that it is unsafe. The case is the latest skirmish in the battle over reproductive rights in the United States.
The appeals court said the Food and Drug Administration (FDA), which approved the abortion pill in 2000 and made it more readily available in 2016, "failed to address several important concerns about whether the drug would be safe for the women who use it."
At a hearing in May, the three judges pushed back against government arguments that the decision on whether to allow the use of mifepristone should be left to the FDA.
The case stems from a ruling by a conservative US District Court judge in Texas that would have banned mifepristone.
The 5th Circuit Court blocked a ban on the abortion pill, but imposed restrictions on access, after which the baton was handed to the Supreme Court, where conservatives wield a 6-3 majority.
The Supreme Court temporarily preserved access to mifepristone, freezing the rulings by the lower courts and sending the case back to the 5th Circuit, whose latest decision will also remain on hold until the nation's highest court decides whether it will hear the case.
It would be the most significant abortion case to reach the nine-member Supreme Court since it overturned the constitutional right to the procedure in June of last year.
Since then, some 20 states, mostly in the South and the Midwest, have prohibited abortion outright or restricted access while others, mainly on the coasts, have moved to protect it.
- 'Exemplary safety' -
Reacting to the 5th Circuit ruling, the Center for Reproductive Rights said there is "scientific CONSENSUS on the exemplary safety and efficacy of mifepristone.
"Medication abortion is used in over half of all abortions in the US and the imposition of outdated, unscientific restrictions will harm millions of the most vulnerable pregnant people in the US," it said.
Katie Daniel, state policy director of the anti-abortion group Susan B. Anthony Pro-Life America, welcomed the court's decision.
"The FDA ignored science and its own rules when it rubber-stamped Democrats' reckless mail-order abortion scheme," Daniel said.
"We won't rest until the FDA and the profit-driven abortion industry are held accountable for the suffering they've inflicted on women and girls, as well as the deaths of countless unborn children," she said.
The FDA estimates that 5.6 million Americans have used it to terminate pregnancies since mifepristone was approved in 2000.
D.Schneider--BTB